Wegovy vs Zepbound: Two FDA Weight-Management Injectables

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub — evidence-based GLP-1 comparisons tied to the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial comparison. PlexusDx has no commercial relationship with Novo Nordisk or Eli Lilly.

Wegovy and Zepbound are the two injectables FDA-approved specifically for chronic weight management — which makes this a rare like-for-like comparison on indication. One is a single-hormone GLP-1 agent, the other a dual-hormone agonist. This review sets semaglutide against tirzepatide on action, label detail, evidence, safety, and cost as of April 2026, then the genetics both share as a starting line.

The two FDA-approved weight-management injectables, side by side

Wegovy is a selective glucagon-like peptide-1 (GLP-1) receptor agonist from Novo Nordisk. Zepbound is a GIP and GLP-1 dual receptor agonist from Eli Lilly. Both engage the GLP-1 receptor across the pancreas, hypothalamus, and gut — slowing gastric emptying, blunting post-meal glucose, and increasing satiety. Tirzepatide-based compounds add GIP-receptor agonism, a defining molecular difference here.

Both cleared for weight — where the labels differ

Wegovy is FDA-approved for chronic weight management (2021) in adults with BMI ≥ 30, or ≥ 27 with at least one weight-related condition. Zepbound is FDA-approved for chronic weight management (2023) under the same BMI criteria, and the FDA expanded its indication in 2024 to include moderate-to-severe obstructive sleep apnea in adults with obesity. These scopes drive how each can be prescribed and whether insurance treats the cost as covered.

STEP and SURMOUNT under the microscope

Wegovy was evaluated in the STEP program (chronic weight management), while Zepbound was evaluated in the SURMOUNT program (chronic weight management, with SURMOUNT-OSA for obstructive sleep apnea). Some comparisons are indirect — the SURMOUNT and STEP programs have been compared indirectly — and SURPASS evaluated tirzepatide head-to-head against semaglutide 1 mg in type 2 diabetes. Populations and endpoints differ, so the cleanest read is per-trial.

Tolerability and the class warning

Both carry the GLP-1 class boxed warning tied to thyroid C-cell tumor risk observed in rodent studies. The most common side effects for each are gastrointestinal — nausea, vomiting, diarrhea, constipation — usually most pronounced during dose escalation. Serious adverse events reported across the class include pancreatitis, gallbladder events, and acute kidney injury in the context of dehydration.

What each lists at, and what you might actually pay

Wegovy's U.S. list price is approximately $1,349 per month as of April 2026 (Novo Nordisk published pricing). Zepbound's U.S. list price is approximately $1,059 per month as of April 2026 (Eli Lilly published pricing). Out-of-pocket cost depends heavily on insurance coverage, manufacturer savings cards, the specific FDA indication on the prescription, and whether a compounded alternative is available through a licensed compounding pathway.

The DNA both share as a starting line

Even between a single- and a dual-hormone agent, the upstream genetics overlap. Variants in GIPR (glucose-dependent insulinotropic polypeptide receptor; influences the GIP arm of incretin signaling — especially relevant for tirzepatide), GLP1R (the GLP-1 receptor gene), FTO (fat-mass and obesity-associated gene), and MC4R (melanocortin receptor central to energy balance) shape baseline appetite and energy expenditure. These are pathway-level markers; they do not predict response to semaglutide, tirzepatide, or any single compound.

PlexusDx offers semaglutide through its Weight Management Protocols, including the Semaglutide Injection protocol. The differentiator is upstream genetic context. Before any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including GIPR, FTO, and MC4R variants that shape your baseline biology. That is the test before you invest approach.

Related reading on PlexusDx: Buy Wegovy Online, Cheap Wegovy, Discount Wegovy, How to Buy Wegovy.

Disclaimer: This is educational content. PlexusDx offers semaglutide through its Weight Management Protocols; this article covers the mechanism, evidence, and genetic context informing any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare formats in the Weight Management Protocols collection, or start upstream with the Precision Peptide Genetic Test.

Frequently Asked Questions

Are both Wegovy and Zepbound approved for weight loss?

Yes. Wegovy earned FDA approval for chronic weight management in 2021, and Zepbound followed in 2023 under the same BMI criteria. Zepbound also gained an expanded 2024 indication for moderate-to-severe obstructive sleep apnea in adults with obesity, which Wegovy's label does not carry.

Does the dual agonist beat the single-hormone agent?

Direct weight-management head-to-head data is limited. SURPASS-2 compared tirzepatide with semaglutide 1 mg in type 2 diabetes and showed larger mean weight reduction with tirzepatide there. Weight programs used different endpoints, and individual response varies — discuss specifics with a healthcare provider.

Can genetics tell me which weight-management drug fits?

No. The Precision Peptide Genetic Test does not predict response to Wegovy, Zepbound, or any medication. It analyzes pathway-level variants in GIPR and FTO, and MC4R that shape baseline incretin and energy-balance biology — context that applies across both compounds regardless of which is prescribed.

How different are the side effects between them?

Profiles are similar across the class, with gastrointestinal symptoms most common; tirzepatide products may show slightly higher rates of certain GI symptoms in some trials. Both carry the boxed warning for thyroid C-cell tumor risk observed in rodent studies. Review your full history with a provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.